Rachel Stadelmaier
Rachel Stadelmaier has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Monica Hsiung Wojcik
Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Divisions of Newborn Medicine and of Genetics and Genomics, Boston Children’s Hospital, Harvard Medical School, B
3 shared publications Anne Hunt
Hunt Consulting Associates, Chapel Hill, North Carolina
1 shared publicationCaroline D. Robson
Department of Radiology Boston Children's Hospital Boston Massachusetts USA
1 shared publicationChristopher J Stodgell
Department of OB/GYN, University of Rochester School of Medicine & Dentistry, Rochester, New York
1 shared publicationCurtis K. Deutsch
The Psychobiology Program at the Eunice Kennedy Shriver Center and Departments of Psychiatry and Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts
1 shared publicationDevon Barrett
Emory University School of Medicine Atlanta Georgia USA
1 shared publication
Latest Publications
- 1 January 2023
- Published by American Academy of Pediatrics (AAP) in NeoReviews
- Vol. 24 (1) , 51-56
Trisomy 13: Survival beyond the NICU
Trisomy 13 is the third most common autosomal aneuploidy disorder and is associated with a number of congenital malformations. Survival of infants with trisomy 13 has improved over time as life-prolonging technological interventions are more commonly offered. In this article, we describe the course of a child with trisomy 13 who has been followed at our hospital since infancy and explore the changing landscape of care for children with trisomy 13.
- 1 January 2023
- Published by American Academy of Pediatrics (AAP) in NeoReviews
- Vol. 24 (1) , 51-56
Trisomy 13: Survival beyond the NICU
Trisomy 13 is the third most common autosomal aneuploidy disorder and is associated with a number of congenital malformations. Survival of infants with trisomy 13 has improved over time as life-prolonging technological interventions are more commonly offered. In this article, we describe the course of a child with trisomy 13 who has been followed at our hospital since infancy and explore the changing landscape of care for children with trisomy 13.
- 9 August 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (12) , 3770-3783
Neuroimaging in Kabuki syndrome and another KMT2D‐related disorder
Recognition of distinct phenotypic features is an important component of genetic diagnosis. Although CHARGE syndrome, Kabuki syndrome, and a recently delineated KMT2D Ex 38/39 allelic disorder exhibit significant overlap, differences on neuroimaging may help distinguish these conditions and guide genetic testing and variant interpretation. We present an infant clinically diagnosed with CHARGE syndrome but subsequently found to have a de novo missense variant in exon 38 of KMT2D, the gene implicated in both Kabuki syndrome and a distinct KMT2D allelic disorder. We compare her brain and inner ear morphology to a retrospective cohort of 21 patients with classic Kabuki syndrome and to typical CHARGE syndrome findings described in the literature. Thirteen of the 21 Kabuki syndrome patients had temporal bone imaging (5/13 CT, 12/13 MRI) and/or brain MRI (12/13) which revealed findings distinct from both CHARGE syndrome and the KMT2D allelic disorder. Our findings further elucidate the spectrum of inner ear dysmorphology distinguishing Kabuki syndrome and the KMT2D allelic disorder from CHARGE syndrome, suggesting that these three disorders may be differentiated at least in part by their inner ear anomalies.
- 9 August 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 185 (12) , 3770-3783
Neuroimaging in Kabuki syndrome and another KMT2D‐related disorder
Recognition of distinct phenotypic features is an important component of genetic diagnosis. Although CHARGE syndrome, Kabuki syndrome, and a recently delineated KMT2D Ex 38/39 allelic disorder exhibit significant overlap, differences on neuroimaging may help distinguish these conditions and guide genetic testing and variant interpretation. We present an infant clinically diagnosed with CHARGE syndrome but subsequently found to have a de novo missense variant in exon 38 of KMT2D, the gene implicated in both Kabuki syndrome and a distinct KMT2D allelic disorder. We compare her brain and inner ear morphology to a retrospective cohort of 21 patients with classic Kabuki syndrome and to typical CHARGE syndrome findings described in the literature. Thirteen of the 21 Kabuki syndrome patients had temporal bone imaging (5/13 CT, 12/13 MRI) and/or brain MRI (12/13) which revealed findings distinct from both CHARGE syndrome and the KMT2D allelic disorder. Our findings further elucidate the spectrum of inner ear dysmorphology distinguishing Kabuki syndrome and the KMT2D allelic disorder from CHARGE syndrome, suggesting that these three disorders may be differentiated at least in part by their inner ear anomalies.
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S93
Optimizing the genetic diagnostic evaluation for critically ill infants
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S93
Optimizing the genetic diagnostic evaluation for critically ill infants
- 21 June 2017
- Published by Wiley in Birth Defects Research
- Vol. 109 (14) , 1134-1143
Exposure to Sodium Valproate during Pregnancy: Facial Features and Signs of Autism
Background: Valproic acid (VPA) is the most teratogenic anticonvulsant drug in clinical use today. Children exposed prenatally to VPA have previously been shown to have dysmorphic craniofacial features, identified subjectively but not by anthropometric methods. Exposure to VPA has also been associated with an increased frequency of autism spectrum disorder (ASD). An increased cephalic index (the ratio of the cranial lateral width to the cranial anterior–posterior length) has been observed in children with ASD.Methods: Forty‐seven children exposed to VPA during the first trimester of pregnancy were evaluated for dysmorphic facial features, identified subjectively and by measurements. Each VPA‐exposed child was evaluated for ASD using the Social Communication Questionnaire, Autism Diagnostic Interview‐Revised, and Autism Diagnostic Observation Schedule. The same physical examination was carried out on an unexposed comparison group of 126 children. The unexposed children also had testing for cognitive performance by the Wechsler Intelligence Scale for Children.Results: Several dysmorphic craniofacial features, including telecanthus, wide philtrum, and increased length of the upper lip were identified subjectively. Anthropometric measurements confirmed the increased intercanthal distance and documented additional findings, including an increased cephalic index and decreased head circumference/height index. There were no differences between the craniofacial features of VPA‐exposed children with and without ASD.Conclusion: An increased frequency of dysmorphic craniofacial features was identified in children exposed to VPA during the first trimester of pregnancy. The most consistent finding was a larger cephalic index, which indicates a disproportion of increased width of the skull relative to the shortened anterior–posterior length. Birth Defects Research 109:1134–1143, 2017.
- 21 June 2017
- Published by Wiley in Birth Defects Research
- Vol. 109 (14) , 1134-1143
Exposure to Sodium Valproate during Pregnancy: Facial Features and Signs of Autism
Background: Valproic acid (VPA) is the most teratogenic anticonvulsant drug in clinical use today. Children exposed prenatally to VPA have previously been shown to have dysmorphic craniofacial features, identified subjectively but not by anthropometric methods. Exposure to VPA has also been associated with an increased frequency of autism spectrum disorder (ASD). An increased cephalic index (the ratio of the cranial lateral width to the cranial anterior–posterior length) has been observed in children with ASD.Methods: Forty‐seven children exposed to VPA during the first trimester of pregnancy were evaluated for dysmorphic facial features, identified subjectively and by measurements. Each VPA‐exposed child was evaluated for ASD using the Social Communication Questionnaire, Autism Diagnostic Interview‐Revised, and Autism Diagnostic Observation Schedule. The same physical examination was carried out on an unexposed comparison group of 126 children. The unexposed children also had testing for cognitive performance by the Wechsler Intelligence Scale for Children.Results: Several dysmorphic craniofacial features, including telecanthus, wide philtrum, and increased length of the upper lip were identified subjectively. Anthropometric measurements confirmed the increased intercanthal distance and documented additional findings, including an increased cephalic index and decreased head circumference/height index. There were no differences between the craniofacial features of VPA‐exposed children with and without ASD.Conclusion: An increased frequency of dysmorphic craniofacial features was identified in children exposed to VPA during the first trimester of pregnancy. The most consistent finding was a larger cephalic index, which indicates a disproportion of increased width of the skull relative to the shortened anterior–posterior length. Birth Defects Research 109:1134–1143, 2017.